Industry Leading R&D Performance (ILRDP) Transformation
The Industry Leading R&D Transformation aligns clients’ R&D with business strategy and identifies operational/maturity improvements through our game-changing framework called the Industry Leading R&D Performance method. ILRDP is populated with all the leading practices within and outside the industry that aid in accelerating clinical trials as well as optimizing the “business of R&D” for the Life Sciences industry. Through the use of our codified delivery methods, tools and assets, we can fully assess your capabilities to create optimal R&D processes and to deliver clinical trials at the lowest Total Cost of Ownership and to ensure the highest probability of success. Our model also contains comprehensive risk management and associated mitigation techniques for every part of a clinical trial, clinical development and the “business of R&D” for your company. Through the ILRDP method, Advanced Clinical is making a positive, sustainable net profit impact for you, our client.
R&D Transformation Components:
The R&D organization’s performance is analyzed with top down (strategic capabilities) and bottom up (operational capabilities) methodology. Additionally, the organization’s position in the industry is examined using competitive assessment, R&D benchmarking and financial analysis. These are then integrated to assess R&D capabilities.
R&D Assessment:
- Identify and quantify transformational requirements from a people, methodology, technology and financial perspective
- Illustrate the value of R&D, including revenue drivers, cost reduction and strategic differentiation enablers
- Assist clients in transforming R&D from a source of product innovation to a source of combined product, business model and operational innovation
From our assessment, we are able to take our clients through the final stages of R&D transformation, creating for them:
- Business case models
- Short-term and long-term strategies
- Roadmaps for future R&D success
Our approach will enable companies to embrace R&D and, in the future, drive their business strategy, identifying new realms for growth and becoming the hub of company-wide innovation efforts.
ILRDP is not just limited to the Life Sciences industry, but has proven efficacy across industries, based on its best practices within and outside of Life Sciences. Look below for some of the tremendous results ILRDP has created for clients:
| Company | Overview | Impact |
| $14.5B Medical Device and Drug were concerned about their R&D management and product development |
|
|
| Large Private Medical Device received two FDA warning letters; recalls abounded; 2-3 years late on average for NPD |
|
|
| $32B Finland-based Mobile Device Manufacturer |
|
|
